See Why AC Immune Stock Is Trading Higher After Data From Alzheimer's Candidate

AC Immune SA ACIU and its collaborating partner Genentech, part of Roche Holdings AG RHHBY, have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).
Semorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.
Safety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.
Semorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.
There was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.
Further analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.
Semorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.
Price Action: ACIU shares are up 59.70% at $11.16 during the premarket session on the last check Tuesday.